Literature DB >> 9875265

Striatal transplantation in a transgenic mouse model of Huntington's disease.

S B Dunnett1, R J Carter, C Watts, E M Torres, A Mahal, L Mangiarini, G Bates, A J Morton.   

Abstract

Striatal grafts have been proposed as a potential strategy for striatal repair in Huntington's disease, but it is unknown whether the diseased brain will compromise graft survival. A transgenic mouse line has recently been described in which hemizygotes with an expanded CAG repeat in exon 1 of the HD gene exhibit a progressive neurological phenotype similar to the motor symptoms of Huntington's disease. We have therefore evaluated the effects of the transgenic brain environment on the survival, differentiation, and function of intrastriatal striatal grafts and undertaken a preliminary analysis of the effects of the grafts on the development of neurological deficits in the host mice. Hemizygote transgenic and wild-type littermate female mice received striatal grafts at 10 weeks of age and were allowed to survive 6 weeks. Normal healthy grafts were seen to survive and differentiate within the striatum of transgenic mice in a manner comparable to that seen in control mice. The transgenic mice exhibited a progressive decline in body weight from 9 weeks of age and a progressive hypoactivity in an open field test of general locomotor behavior. Although striatal grafts exerted a statistically significant influence on several indices of this impairment, all behavioral effects were small and did not exert any clinically relevant effect on the profound neurological deficiency of the transgenic mice.

Entities:  

Mesh:

Year:  1998        PMID: 9875265     DOI: 10.1006/exnr.1998.6926

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  31 in total

1.  Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.

Authors:  R J Carter; L A Lione; T Humby; L Mangiarini; A Mahal; G P Bates; S B Dunnett; A J Morton
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Authors:  Kc Biju; Qing Zhou; Guiming Li; Syed Z Imam; James L Roberts; William W Morgan; Robert A Clark; Senlin Li
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

3.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

Review 4.  Neural transplantation in patients with Huntington's disease.

Authors:  Anne E Rosser; Stephen B Dunnett
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 5.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

6.  Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease.

Authors:  Kyle D Fink; Andrew T Crane; Xavier Lévêque; Dylan J Dues; Lucas D Huffman; Allison C Moore; Darren T Story; Rachel E Dejonge; Aaron Antcliff; Phillip A Starski; Ming Lu; Laurent Lescaudron; Julien Rossignol; Gary L Dunbar
Journal:  Stem Cells Transl Med       Date:  2014-03-21       Impact factor: 6.940

Review 7.  Cell therapy in Huntington's disease.

Authors:  Stephen B Dunnett; Anne E Rosser
Journal:  NeuroRx       Date:  2004-10

8.  Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

Authors:  K C Biju; Rene A Santacruz; Cang Chen; Qing Zhou; Jiemin Yao; Sara L Rohrabaugh; Robert A Clark; James L Roberts; Kimberley A Phillips; Syed Z Imam; Senlin Li
Journal:  Neurosci Lett       Date:  2013-01-04       Impact factor: 3.046

9.  Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.

Authors:  Jennifer L Wacker; Shao-Yi Huang; Andrew D Steele; Rebecca Aron; Gregor P Lotz; QuangVu Nguyen; Flaviano Giorgini; Erik D Roberson; Susan Lindquist; Eliezer Masliah; Paul J Muchowski
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

10.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.